Pharma Fridays — February 7, 2025

February 7, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves New Treatment Option For A Leading Cause of Diabetes-Related Blindness Genentech, a member of the Roche Group on February 4 announced that the U.S. Food and Drug Administration (FDA) approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Pharma Fridays

←Going With the Flow: MSEP Off to a Strong Start!

Stay Connected with the Society’s Curated Communications Channels→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today